Compositions and methods for administration of vaccines against dengue virus
Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
1. A method for inducing an immune response in a subject against three or more dengue virus serotypes, comprising,
administering to the subject by at least a first intradermal introduction, a first immunogenic composition of a mixture of three or more live, attenuated dengue viruses, the composition comprising at least one dengue-dengue chimera and three or more different dengue virus serotype in the mixture, and administering at least a second intradermal introduction(s) of a second immunogenic composition against one or more dengue virus serotypes within 30 days after the first administration of the first immunogenic composition to the subject and inducing an immune response in the subject against three or more dengue virus serotypes.
2. The method of claim 1 , wherein administering the at least a second intradermal introduction(s) of the second immunogenic composition occurs in the same anatomical area as the first intradermal introduction of the first immunogenic composition.
3. The method of claim 1 , wherein administering the at least a second intradermal introduction(s) of the second immunogenic composition occurs at a separate anatomical site on the subject as the first intradermal introduction, and wherein the second intradermally-administered composition engages different lymph nodes than those engaged by the first intradermally-administered composition.
4. The method of claim 1 , wherein the first immunogenic composition comprises at least three dengue virus serotypes at a predetermined ratio.
5. The method of claim 1 , wherein the first immunogenic composition comprises all four dengue virus serotypes, a tetravalent formulation.
6. The method of claim 1 , further comprising administering at least one additional immunogenic agent to the subject as part of, or separately from the first immunogenic composition.
7. The method of claim 6 , wherein the additional immunogenic agent comprises at least one Toll receptor (TLR) ligand(s) and the additional immunogenic agent is added to the first immunogenic composition prior to administration to the subject.
8. The method of claim 1 , wherein the mixture of three or more live, attenuated dengue viruses comprises a live, attenuated dengue-2 virus, and at least one dengue-dengue chimeric virus wherein capsid and non-structural proteins are from the live, attenuated dengue-2 virus, and wherein the backbone of the dengue-dengue chimera is dengue-2; and pre-membrane and envelope proteins are from at least a second, different dengue virus serotype.
9. The method of claim 8 , wherein the pre-membrane and envelope proteins of the at least a second dengue virus are from dengue-1, dengue-3 or dengue-4.
10. The method of claim 8 , wherein the at least one dengue-dengue chimeric viruses are two or more of dengue-2/dengue-1, dengue-2/dengue-3 and dengue-2/dengue-4.
11. A method for inducing an immune response in a subject against dengue virus serotypes, comprising,
administering to the subject by at least a first intradermal introduction, a single immunogenic composition of four live, attenuated dengue viruses wherein the composition comprises live, attenuated dengue-2 virus wherein the live, attenuated dengue-2 virus is not chimeric; and three dengue-dengue chimeras of live, attenuated dengue viruses of dengue 1, dengue 3 and dengue 4 and inducing an immune response in the subject against all four dengue virus serotypes.
12. The method of claim 11 administering at least a second immunogenic composition in the same anatomical area as the first intradermal introduction.
13. The method of claim 11 , administering at least a second immunogenic composition intradermally at a separate anatomical area on the subject from the first intradermal introduction, and wherein the second intradermally-administered composition engages different lymph nodes than engaged by the first intradermally-administered composition.
14. The method of claim 11 , wherein the dengue serotypes of the immunogenic composition comprise a predetermined ratio of one dengue virus serotype to another dengue virus serotype in the single composition.
15. The method of claim 1 , wherein the first immunogenic composition and the second immunogenic composition comprise the same formulation.
16. The method of claim 1 , wherein the first immunogenic composition and the second immunogenic composition comprise the same formulation, and wherein dengue-4 is present in the formulation at a concentration that is higher than the concentration of dengue-2 in the formulation.
17. The method of claim 1 , wherein the first immunogenic composition and the second immunogenic composition comprise different formulations.
18. The method of claim 1 , further comprising administering at least one additional immunogenic agent to the subject as part of, or separately from the second immunogenic composition.
19. The method of claim 11 , further comprising administering at least a second immunogenic composition against dengue virus within 30 days after the first administration of the single immunogenic composition.